Hyperprogression and Immunotherapy: Fact, Fiction, or Alternative Fact?-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Hyperprogression and Immunotherapy: Fact, Fiction, or Alternative Fact?

Published:2020-03 Issue:3 Volume:6 Page:181-191
ISSN:2405-8033
Container-title:Trends in Cancer
language:en
Short-container-title:Trends in Cancer

Author:

Adashek Jacob J.,Subbiah Ishwaria M.,Matos Ignacio,Garralda Elena,Menta Arjun K.,Ganeshan Dhakshina Moorthy,Subbiah Vivek^ORCID

Funder

Novartis/Rochel

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference26 articles.

1. Hyperprogressive disease is a new pattern of progression in cancer patients treated by anti-PD-1/PD-L1;Champiat;Clin. Cancer Res.,2017

2. Hyperprogressors after immunotherapy: analysis of genomic alterations associated with accelerated growth rate;Kato;Clin. Cancer Res.,2017

3. Hyperprogressive disease in patients with advanced non-small cell lung cancer treated with PD-1/PD-L1 inhibitors or with single-agent chemotherapy;Ferrara;JAMA Oncol.,2018

4. Hyperprogressive disease (HPD) in early-phase immunotherapy (IO) trials;Kanjanapan;J. Clin. Oncol.,2018

5. Incidence and clinical implications of a new definition of hyperprogression (HPD) with immune checkpoint inhibitors (ICIs) in patients treated in phase 1 (Ph1) trials;Matos;J. Clin. Oncol.,2018

Cited by 91 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Strategies for engineering oncolytic viruses to enhance cancer immunotherapy;Frontiers in Pharmacology;2024-09-06

2. Development and validation of a new tool to estimate early mortality in patients with advanced cancer treated with immunotherapy;2024-07-16

3. A Review of Immunotherapy in Non-Small-Cell Lung Cancer;Current Oncology;2024-06-17

4. Breast Cancer Immune Landscape: Interplay Between Systemic and Local Immunity;Advanced Biology;2024-05-10

5. The long and winding road to biomarkers for immunotherapy: a retrospective analysis of samples from patients with triple-negative breast cancer treated with pembrolizumab;ESMO Open;2024-05

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3